Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants

Published:2024-11 Issue: Volume:229 Page:116499
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Ford Brian E.,Chachra Shruti S.,Alshawi Ahmed,Oakley Fiona,Fairclough Rebecca J.,Smith David M.,Tiniakos Dina,Agius Loranne^ORCID

Funder

Newcastle University

UKRI Medical Research Council

Publisher

Elsevier BV

Reference62 articles.

1. Targeting the pancreatic β-cell to treat diabetes;Vetere;Nat. Rev. Drug. Discov.,2014

2. Assessing the potential of glucokinase activators in diabetes therapy;Matschinsky;Nat. Rev. Drug. Discov.,2009

3. A patent review of glucokinase activators and disruptors of the glucokinase–glucokinase regulatory protein interaction: 2011–2014;Filipski;Expert. Opin. Ther. Pat.,2014

4. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial;Zhu;Nat. Med.,2022

5. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial;Yang;Nat. Med.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP